Elanco Animal Health
$ 22.12
-8.60%
07 Aug - close price
- Market Cap 12,086,680,000 USD
- Current Price $ 22.12
- High / Low $ 24.41 / 22.02
- Stock P/E N/A
- Book Value 13.02
- EPS -0.41
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.04 %
- 52 Week High 27.98
- 52 Week Low 16.89
About
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.
Analyst Target Price
$30.07
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-24 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-26 | 2023-11-07 |
| Reported EPS | 0.34 | 0.4 | 0.13 | 0.19 | 0.26 | 0.37 | 0.14 | 0.13 | 0.3 | 0.34 | 0.08 | 0.18 |
| Estimated EPS | 0.27 | 0.34 | 0.1135 | 0.13 | 0.2 | 0.3 | 0.1486 | 0.12 | 0.24 | 0.27 | 0.11 | 0.12 |
| Surprise | 0.07 | 0.06 | 0.0165 | 0.06 | 0.06 | 0.07 | -0.0086 | 0.01 | 0.06 | 0.07 | -0.03 | 0.06 |
| Surprise Percentage | 25.9259% | 17.6471% | 14.5374% | 46.1538% | 30% | 23.3333% | -5.7873% | 8.3333% | 25% | 25.9259% | -27.2727% | 50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELAN
2026-08-07 02:40:16
Elanco Animal Health Inc (ELAN) shares recently fell 7.7% to $24.20, making it 8.5% down for the week. The stock is currently deemed significantly overvalued with a GF Value™ of $15.62, despite having an above-average GF Score™ of 66/100. While insider activity shows purchases, suggesting some confidence, the company's unprofitability and negative cash flow raise concerns about its valuation and sustainability for investors.
2026-08-06 20:40:16
Elanco Animal Health Inc. reported a 10% increase in second-quarter revenue to $1.37 billion, leading the company to raise its full-year financial guidance for the second time. The growth was attributed to strong performance of new products like Zenrelia and Credelio Quattro, as well as significant increases in Pet Health and Farm Animal segments. Elanco now expects full-year revenue between $5.09 billion and $5.14 billion and has also increased its adjusted EBITDA and EPS targets.
2026-08-06 14:40:16
UBS has increased its price target for Elanco Animal Health to $33 from $31, while reiterating a Buy rating on the stock. This adjustment follows Elanco's Q2 2026 earnings call, where the company reported rising adjusted earnings and revenue and lifted its 2026 outlook. Elanco Animal Health is an animal health company focused on preventing and treating diseases in both farm animals and pets.
2026-08-06 04:16:09
Elanco Animal Health's stock rose 2.4% following its Q2 2026 report, which showed significant improvement in adjusted EBITDA and gross margin, despite trailing losses. The company's "Big 6" portfolio and new products like Zenrelia and Credelio Quattro are driving revenue growth and market penetration. While progress in margin and debt reduction is evident, concerns remain about the sustainability of profitability and the company's leveraged balance sheet.
2026-08-05 15:16:09
Elanco Animal Health (NYSE:ELAN) shares reached a new 52-week high after reporting strong quarterly earnings of $0.34 EPS, surpassing estimates, with revenue rising 10.2% to $1.37 billion. The company provided Q3 and full-year 2026 EPS guidance, and analysts maintain a "Moderate Buy" rating with an average price target of $28.73. Insider purchases by CEO Jeffrey N. Simmons and Rajeev A. Modi, along with significant institutional ownership, highlight confidence in the company.
2026-08-05 14:16:09
Elanco Animal Health (ELAN) has reported its second-quarter 2026 results. The article also briefly mentions Unity Software (U.US) which reported fourth-quarter revenue of $609 million, exceeding estimates, despite a quarterly loss of 66 cents per share. Full details of the Elanco report are behind a login wall due to copyright.
